Rosetta and Moffitt Partner to Develop microRNA Cancer Diagnostic
|
By LabMedica International staff writers Posted on 16 Jun 2014 |
|
Rosetta Genomics, Ltd. (Princeton, NJ, USA; Rehovot, Israel), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, has entered into an agreement with Moffitt Cancer Center (Tampa, FL, USA) to advance the development and commercialization of Rosetta's thyroid neoplasia assay. Rosetta will work with Marino Leon, MD, associate member of the department of anatomic pathology at Moffitt.
Kenneth A. Berlin, president and CEO of Rosetta Genomics commented, “Results from our initial studies demonstrated that microRNA expression levels can differentiate malignant nodules from benign nodules, and also demonstrated our ability to extract and profile microRNAs from thyroid fine-needle aspirations [FNAs] in various sample types and in a way consistent with common clinical practices. This agreement with Moffitt will help us further advance the development of this important assay, and should allow us to achieve our goal of launching this important assay prior to the end of 2015.”
Dr. Marino Leon noted, “Many patients with indeterminate thyroid FNA results are sent to surgery as a precaution, despite the fact that the majority of these cases are benign. This exposes patients to unnecessary surgical risk and costs the system hundreds of millions of dollars.”
Rosetta Genomics cancer tests are a series of microRNA-based diagnostic testing services. The Rosetta Cancer Origin test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The company’s assays are offered directly by Rosetta Genomics in the United States, and through distributors around the world. Rosetta’s cancer testing services are commercially available through its Philadelphia (PA, USA)-based College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA)-certified lab.
Rosetta’s research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.
Moffitt is one of only 41 US National Cancer Institute-designated comprehensive cancer centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in US News & World Report as one of “America's Best Hospitals” for cancer since 1999.
Related Links:
Rosetta Genomics
Moffitt Cancer Center
Kenneth A. Berlin, president and CEO of Rosetta Genomics commented, “Results from our initial studies demonstrated that microRNA expression levels can differentiate malignant nodules from benign nodules, and also demonstrated our ability to extract and profile microRNAs from thyroid fine-needle aspirations [FNAs] in various sample types and in a way consistent with common clinical practices. This agreement with Moffitt will help us further advance the development of this important assay, and should allow us to achieve our goal of launching this important assay prior to the end of 2015.”
Dr. Marino Leon noted, “Many patients with indeterminate thyroid FNA results are sent to surgery as a precaution, despite the fact that the majority of these cases are benign. This exposes patients to unnecessary surgical risk and costs the system hundreds of millions of dollars.”
Rosetta Genomics cancer tests are a series of microRNA-based diagnostic testing services. The Rosetta Cancer Origin test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The company’s assays are offered directly by Rosetta Genomics in the United States, and through distributors around the world. Rosetta’s cancer testing services are commercially available through its Philadelphia (PA, USA)-based College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA)-certified lab.
Rosetta’s research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.
Moffitt is one of only 41 US National Cancer Institute-designated comprehensive cancer centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in US News & World Report as one of “America's Best Hospitals” for cancer since 1999.
Related Links:
Rosetta Genomics
Moffitt Cancer Center
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
HPV Test
Allplex HPV28 Detection
Latest Industry News
- Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
- Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
- Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
- Merck KGaA to Acquire Bio-Techne, Expanding Life Science Portfolio
- Agilent Strengthens Pathology Capabilities Through Biocare Acquisition
- Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
- Project Aims to Develop First Single-Cell Assay for ADC Therapies
- Agreement Supports pTau217-Based Alzheimer’s Blood Test Development
- Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing
- Partnership Aims to Improve Transplant Monitoring Across Care Continuum
- QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
- Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies
- Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
- Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
- Open-Source Consortium Aims to Standardize Digital Pathology Workflows
- Diazyme Laboratories Acquires Carolina Liquid Chemistries
Channels
Clinical Chemistry
view channel
Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, triggering inflammation, pain, and scarring. Diagnosis often relies on surgery and, in the UK, takes an average of... Read more
Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for the Access p‑Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms... Read more
Molecular Diagnostics
view channel
Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. Genetic testing clarifies many drivers, yet it... Read more
Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more
Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
Lung cancer remains a leading cause of cancer death, and early-stage disease often produces few symptoms, complicating timely diagnosis and risk stratification. Conventional imaging and tissue biopsy have... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
CE-Marked Blood Assay Automates Tuberculosis Infection Testing
Tuberculosis continues to pose a major global health challenge, with an estimated 10.7 million people falling ill and 1.23 million deaths in 2024. Roughly one quarter of the world’s population is believed... Read more
Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Genomic surveillance is essential for detecting viral variants before they spread widely, yet many public health systems face high costs, uneven capacity, and computational barriers. Existing analytic... Read more
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read morePathology
view channel
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
EBV Status Helps Predict Survival in Primary CNS Lymphoma
Primary central nervous system lymphoma is a rare malignancy in which tumors arise in the brain and, less often, the spinal cord, eyes, or cerebrospinal fluid. Outcomes are especially variable when the... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
